Another great achievement by the hard working employees of $ATOS.
Dosing the first patient in this trial marks a significant milestone for Atossa in support of our important partnership with the iSPY Network and QLHC. The innovative idea of combining (Z)-endoxifen and Lilly's FDA approved abemaciclib in the neoadjuvant setting can open the door to the development of gentler more patient-friendly treatment options for women with invasive breast tumors. By combining these therapies, we hope to achieve improved outcomes compared to available therapies, not only in terms of safety and efficacy, but also with respect to patients’ quality of life outcome measures. https://lnkd.in/gxRSU7eB